Biochemistry of Pulmonary Emphysema
Springer (Publisher)
Published on 14. October 1992
Book
Hardback
XV, 200 pages
978-3-540-19775-1 (ISBN)
Description
Pulmonary emphysema is a disease which develops because of a localized imbalance between endogenous proteinase inhibitors and proteinases leaking from neurophils during phagocytosis at inflammatory foci within the lung. This volume not only reviews at a biochemical level what is known about the natural inhibitors and proteinases involved in connective tissue destruction within the lung, but also suggests novel methodologies for reestablishing proper enzyme-inhibitor balance, including the use of natural or synthetic inhibitors for supplementation or gene therapy.
More details
Series
Edition
1st Edition.
Language
English
Place of publication
London
United Kingdom
Publishing group
Springer Berlin
Target group
Professional and scholarly
Research
Illustrations
26
13 s/w Abbildungen, 26 s/w Tabellen
41 illustrations, 26 tables
Dimensions
Height: 24.2 cm
Width: 17 cm
Weight
665 gr
ISBN-13
978-3-540-19775-1 (9783540197751)
DOI
10.1007/978-1-4471-3771-9
Schweitzer Classification
Other editions
Additional editions

C. Grassi | J. Travis | L. Casali
Biochemistry of Pulmonary Emphysema
Book
04/2014
Springer
€53.49
Shipment within 15-20 days

C. Grassi | J. Travis | L. Casali
Biochemistry of Pulmonary Emphysema
E-Book
11/2013
Springer
€53.49
Available for download
Persons
Content
From the Contents: Pulmonary Emphysema: What's going on.- Elastin and the Lung.- An Introduction to the Endopeptidases.- Lung Proteinase and Emphysema.- Multiple Functions of Neutrophil Proteinases and their Inhibitor Complexes.- Kinetics of the Interaction of Human Leucocyte Elastase with Protein Substrates.- Proteinase Inhibitor Candidates for Therapy of Enzyme-Inhibitor Imbalances.- Antileucoprotease (Secretory Leucocyte Proteinase Inhibitor), A Major Proteinase Inhibitor in the Human Lung.- Development and Evaluation of Antiproteases as Drugs for Preventing Emphysema.- Genetic Control of Human Alpha-1-Antitrypson and Hepatic Gene Therapy.- Neutrophils, Neutrophil Elastase and the Fragile Lung.